RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Effects of chronic varenicline treatment on nicotine, cocaine, and concurrent nicotined plus cocaine self-administration
Mello, N. K., Fivel, P. A., Kohut, S. J., & Carroll, F. I. (2014). Effects of chronic varenicline treatment on nicotine, cocaine, and concurrent nicotined plus cocaine self-administration. Neuropsychopharmacology, 39(5), 1222-1231. https://doi.org/10.1038/npp.2013.325
Nicotine dependence and cocaine abuse are major public health problems, and most cocaine abusers also smoke cigarettes. An ideal treatment medication would reduce both cigarette smoking and cocaine abuse. Varenicline is a clinically available, partial agonist at alpha 4 beta 2* and alpha 6 beta 2* nicotinic acetylcholine receptors (nAChRs) and a full agonist at alpha 7 nAChRs. Varenicline facilitates smoking cessation in clinical studies and reduced nicotine self-administration, and substituted for the nicotine-discriminative stimulus in preclinical studies. The present study examined the effects of chronic varenicline treatment on self-administration of IV nicotine, IV cocaine, IV nicotine + cocaine combinations, and concurrent food-maintained responding by five cocaine- and nicotine-experienced adult rhesus monkeys (Macaca mulatto). Varenicline (0.009-0.04 mg/kg/h) was administered intravenously every 20 min for 23 h each day for 7-10 consecutive days. Each varenicline treatment was followed by saline-control treatment until food- and drug-maintained responding retumed to baseline. During control treatment, nicotine + cocaine combinations maintained significantly higher levels of drug self-administration than nicotine or cocaine alone (P